The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2022 | Clinical applications of pentose phosphate pathway activation in immunotherapy
Recent research has revealed PKM2 inhibition to increase PD-1 blockade via activation of the pentose phosphate pathway. Geoffrey Markowitz, PhD, Weill Cornell Medicine, New York City, NY, describes the potential implications of PKM2 inhibition in the clinic. Various pentose phosphate antagonists are currently being tested in immune organoid models and tumor-infiltrating lymphocytes (TILs) can potentially be extracted from patients to be infused with pentose phosphate antagonists to enhance immune cell activity. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
